株式会社ジーエヌアイグループ 2025年12月期第２四半期決算説明資料

This document is the financial results presentation for the second quarter of the fiscal year ending December 2025 for GNI Group Ltd. It includes an overview of the company, highlights of the financial results, segment performance, growth strategies, and forecasts for the current fiscal year. The document emphasizes the company's focus on pharmaceutical research, development, and distribution, highlighting key products such as the pulmonary fibrosis treatment drug, Esuliy (Pirfenidone), and the liver fibrosis treatment candidate, F351. Additionally, it outlines strategies for building a global management structure and achieving sustainable growth.